Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)

Table 4 Treatment outcomes by treatment line

	1st line	2nd line	3rd line	4th or higher line
	N = 145	N = 83	N = 49	N = 52^a
Time to relapse (months; median [range])	12.1 [1.1–72.2]^b	8.2 [1.2–37.9]	4.1 [0.5–27.7]	3.4 [0.7–23.2]
Treatment-free interval^c	N = 46^b	N = 62	N = 35	N = 42
(months; median [range])	10.2 [0.7–49.0]	2.9 [0.0–29.8]	1.0 [0.0–10.6]	1.0 [0.0–18.4]
Response at end of therapy	N = 89	N = 61	N = 33	N = 36
Complete response (CR)	3 (3.4%)	None	None	None
Partial response (PR)	19 (21.3%)	8 (13.1%)	None	None
Stable disease (SD)	19 (21.3%)	10 (16.4%)	4 (12.1%)	3 (8.3%)
Progressive disease	48 (54.0%)	43 (70.5%)	29 (87.9%)	33 (91.7%)
CP + PR	22 (24.7%)	8 (13.1%)	None	None
CP + PR + SD	41 (46.0%)	18 (29.5%)	4 (12.1%)	3 (8.3%)

^aas all treatment lines ≥ 4 were counted, the same individual patient may have been counted multiple times with multiple treatment lines
^bData only for patients without metastases at diagnosis
^cTime between end of the previous systemic treatment and start of current treatment line (for 1st line: duration from initial diagnosis to first systemic therapy)

ISSN: 1471-2407